Interview
with Neil Love, MD Breast Cancer Update for Medical Oncologists,
Program 6 2000
Play
Audio Below:
You
could take tamoxifen, for example, and you know, if you look at
the clinical benefit rate that includes prolonged stable disease
in metastatic breast cancer, tamoxifen may give you a 50 percent
response rate in ER-positive disease that lasts for a year or a
little bit longer. That’s not terribly exciting. But when you’re
using it in the adjuvant situation in patients who have ER-positive
tumors, you get a 40 to 50 percent annual reduction in the odds
of recurrence, and those that have a high ER expression, you get
a 60 percent reduction in the annual odds of recurrence, that’s
significantly better than chemotherapy, even in young women. And
so, yes, if you had an endocrine therapy, no matter what it is,
that’s a little bit better than that, then there could be a
big impact in the adjuvant situation, much bigger than you would
predict from data in metastatic disease.
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct. In process
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
